Insight journal - Dealtalk

Roche CEO may seek rare disease deals

Posted on 28 October 2013

Tags: , , ,

Swiss drugmaker Roche Holding AG would not exclude a move into treatments for rare diseases, its CEO said on Wednesday, even if this represented very small numbers of patients.

Chief executive Severin Schwan told a news conference in Paris that Roche's main criteria in terms of disease was not the size of the patient population but how much additional value and medical benefit could be generated for the individual patient.

Asked if that meant he did not exclude a move into rare diseases, he said: "We go where the science takes us, wherever it is, independent from the size of the patient population."

There has been speculation that Roche might branch out into the lucrative area of rare or so-called orphan diseases after reports it was considering bids for two U.S.-based companies.

Shares in biotechnology group Alexion Pharmaceuticals jumped in July after people familiar with the matter said Roche was seeking financing for a possible bid. No offer has emerged.

Roche has also been linked to BioMarin Pharmaceuticals, although the company denied last month it was raising financing for a bid following a report.

Schwan declined to comment specifically on whether the company was interested in buying Alexion or BioMarin.

High prices and lower development and marketing costs of treatments for orphan diseases are drawing the attention of big pharmaceutical companies as older drugs lose patent protection.

But Roche's group head of pharmaceuticals said in an interview last month that treating ultra-rare diseases was a distinct business from Roche's current area of expertise.

The Basel-based firm is looking to branch out beyond its core cancer drugs and Schwan highlighted the group's focus on autoimmune and inflammatory diseases as well as neuroscience.

"So in those three areas naturally we are a partner of choice for many companies. But again, if there was an interesting opportunity outside of those established areas, I would be very open to look at it," he said.

Read full articles at Reuters

 

Related

Report: Partnering Deals and Alliances with Roche

Report: Partnering Deals and Alliances with Big Pharma

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new1gif
e79banner300x150gif
e78banner300x150animgif